Clinical Trial Update: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating CC-92480 in combination with standard treatments for relapsed/refractory and newly diagnosed multiple myeloma to determine recommen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-92480

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING